Brief: Revive Therapeutics Announces Irb Approval For Phase 3 Clinical Trial Protocol For Bucillamine In Covid-19
31/08/2020 13:37
Aug 31 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES IRB APPROVAL FOR PHASE 3
CLINICAL
TRIAL PROTOCOL FOR BUCILLAMINE IN COVID-19
Source text for Eikon: ID:nGNX7JnC9L
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure